Management plan following initiation of DOAC Therapy

The direct oral anticoagulants (DOACs; apixaban, betrixaban, dabigatran, edoxaban, rivaroxaban) do not require the specialized long-term monitoring and management services provided by the UW Medicine Anticoagulation Clinics. UW Medicine Anticoagulation Services provides the following on a consultative basis:

1) consults to providers regarding DOAC drug selection, dosing, drug interactions, and peri-procedural issues

2) support and instructions to patients and providers for switching patients among the various oral agents

3) DOAC patient education, both telephonic and in person

Patient education materials, specific to each DOAC and developed by UW Medicine Anticoagulation Services, are available on this website in the Patient Education tab.

Guidelines for long-term management of DOACs, developed by UW Medicine Anticoagulation Services and intended to be used by MDs/RNs/MAs in primary or specialty care clinics, are available below.